Investors in the cell therapy industry are actively looking into solid tumours, autoimmune indications and novel engineering as the best place to allocate their money and resources. This, along with the recent investments in Enara Bio, ArsenalBio, Kyverna and Artiva signifies that the field is poised to regain momentum.

It’s not just investments that are gaining traction. Recent approvals are changing the game, with Iovance and Adaptimmune making strides in treating solid tumours, Kite securing first-line treatment approval, and donor cell therapies, demonstrating success in putting autoimmune diseases into remission. The industry is brimming with new hope!

The 8th CAR-TCR Summit Europe returns to London this February as your must-attend forum to remain on the pulse of recent innovation in cell therapy. Join us to collaborate, innovate, and overcome the shared challenges of safety concerns, high cost of goods, effective tumour targeting, and more. Let’s work together to drive success in clinical trials, secure regulatory approvals, and position cell therapy as the first-line treatment for oncological and non-oncological indications.